摘要
抗血管内皮生长因子(VEGF)药物是糖尿病黄斑水肿(DME)的一线治疗方案。光学相干断层扫描成像(OCTA)生物学指标如黄斑区血管密度、中央凹无血管区面积等,可通过识别微血管的改变评估DME的进展。抗VEGF药物治疗DME后,患者的视功能与微血管解剖参数相关,提示OCTA生物学指标在DME的发展及治疗中的预测功能。本文对OCTA在抗VEGF药物治疗DME中的研究进展进行综述。
Anti-vascular endothelial growth factor(VEGF)drugs are the first-line treatment for diabetic macular edema(DME).Optical coherence tomography angiography(OCTA)biological markers,such as macular vascular density,foveal avascular zone area etc.,can assess the progression of DME by identifying microvascular alterations.After anti-VEGF drug treatment with DME,the patient’s visual function is related to microvascular anatomical parameters.This indicates the predictive function of OCTA biological indicators in the development and treatment of DME.This article reviews the research progress of OCTA in the treatment of DME with anti-VEGF drugs.
作者
张妮娜
高璐
陈兆乾
张文芳
ZHANG Nina;GAO Lu;CHEN Zhaoqian;ZHANG Wenfang(The Second Hospital&Clinical Medical School,Lanzhou Universtiy,Gansu Province,Lanzhou730030,China;Department of Ophthalmology,the Second Hospital of Lanzhou Universtiy,Gansu Province,Lanzhou730030,China)
出处
《中国医药导报》
CAS
2024年第32期74-76,86,共4页
China Medical Herald
关键词
光学相干断层扫描成像
糖尿病黄斑水肿
抗血管内皮生长因子
脉络膜
Optical coherence tomography angiography
Diabetic macular edema
Anti-vascular endothelial growth factor
Choroid
